TABLE 3.

Susceptibility profiles and MBL production of blaIMP-9-carrying P. aeruginosa isolates and their transconjugants

OrganismHospitalaWardIsolation date (day/mo/yr)Sexb age (yr)OriginMBL test resultMIC of β-lactam (μg/ml)c
IMPMEMATMCAZCTXTZPCar
96H1NICUd03/04/00M/65Sputum+32882562561281,024
96TTrans+3284256256641,024
121H1NICU17/03/00M/60Sputum+16832256256256NDe
101H1NICU05/06/00M/68Sputum+1621632256128ND
3584H2GMh31/09/00M/85Sputum+84322562561281,024
3584TTrans+ (ph)f4482562561281,024
3695H2GM-/-/00M/60Sputum+8116256256128ND
6104H4NICU13/06/00M/60Sputum+8441286432ND
6104TTrans+ (ph)1241321ND
67H7ICU10/10/00M/68Sputum+641641282561281,024
67TTrans+ (ph)16441282561281,024
50814RecipientNCTCg0.50.1250.52ND0.5<4
  • a H, hospital; numbers 1 to 11 were allocated to the 11 participating hospitals. Trans, transconjugant.

  • b M, male; F, female.

  • c IMP, Imipencm; MEM, meropenem; ATM, aztreonam; CAZ, ceftazidime; CTX, cefotaxime; TZP, piperacillin-tazobactam; CAR, carbenicillin.

  • d NICU, neurology intensive care unit.

  • e ND, not determined.

  • f ph, phantom effect (a “keyhole” appears in the middle of the MBL test strip).

  • g NCTC, National Collection of Type Culture.

  • h GM, geriatric medicine.